Amibegron
Chemical compound
- none
- Development terminated
- Ethyl ([(7S)-7-([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy)acetate
- 121524-08-1 Y
- HCl: 121524-09-2 Y
- 3035442
- 568
- 108738 Y
- PDQ3ME68U3
- HCl: N910CJ679E Y
- D08851 Y
- ChEMBL545437 Y
- DTXSID6047361
- Interactive image
- CCOC(=O)COc3ccc1CCC(Cc1c3)NCC(O)c2cc(Cl)ccc2
InChI
- InChI=1S/C22H26ClNO4.ClH/c1-2-27-22(26)14-28-20-9-7-15-6-8-19(11-17(15)12-20)24-13-21(25)16-4-3-5-18(23)10-16;/h3-5,7,9-10,12,19,21,24-25H,2,6,8,11,13-14H2,1H3;1H/t19-,21-;/m0./s1 Y
- Key:NQIZCDQCNYCVAS-RQBPZYBGSA-N Y
Amibegron (SR-58,611A) was a drug developed by Sanofi-Aventis (now Sanofi) which acts as a selective agonist for the β3 adrenergic receptor. It is the first orally active β3 agonist developed that is capable of entering the central nervous system, and has antidepressant and anxiolytic effects.[1][2]
On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.[3]
References
- ^ Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, et al. (February 2008). "Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders". Neuropsychopharmacology. 33 (3): 574–87. doi:10.1038/sj.npp.1301424. PMID 17460614.
- ^ Overstreet DH, Stemmelin J, Griebel G (June 2008). "Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression". Pharmacology, Biochemistry, and Behavior. 89 (4): 623–6. doi:10.1016/j.pbb.2008.02.020. PMID 18358519. S2CID 35026036.
- ^ Second quarter 2008 results. July 31, 2008, retrieved March 9, 2009.
- v
- t
- e
Specific reuptake inhibitors and/or receptor modulators | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
Miscellaneous | |
---|---|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This article about an anxiolytic is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e